BGB-B2033-101
Recruiting
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Study ID
BGB-B2033-101
ClinicalTrials.gov ID
EudraCT or EUCT Number
2025-524136-19-00
Study Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No
No Study Documents
Locations
Study Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No
No Study Documents